Fibrosis - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 122 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis - Pipeline Review, H2 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.

Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 29, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Fibrosis - Overview 7
Fibrosis - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Fibrosis - Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Fibrosis - Companies Involved in Therapeutics Development 28
Acceleron Pharma Inc 28
Aelis Farma SAS 28
Anima Biotech Ltd 28
Bristol-Myers Squibb Company 29
Cellmid Ltd 29
Clementia Pharmaceuticals Inc 30
Complexa Inc 30
Confo Therapeutics 31
EA Pharma Co Ltd 31
Five Prime Therapeutics Inc 31
Genfit SA 32
GlycoMimetics Inc 32
iBio Inc 33
Inception Sciences Inc 33
Isarna Therapeutics GmbH 34
Kadmon Corp LLC 34
Kalyra Pharmaceuticals Inc 34
Morphic Therapeutic Inc 35
Neumedicines Inc 35
Novartis AG 36
Palatin Technologies Inc 36
Proximagen Ltd 37
Redx Pharma Plc 37
Ribomic Inc 37
Scholar Rock Inc 38
SciFluor Life Sciences LLC 38
SK Chemicals Co Ltd 38
Symic Biomedical Inc 39
Fibrosis - Drug Profiles 40
ACE-2798 - Drug Profile 40
AEF-0118 - Drug Profile 41
AK-002 - Drug Profile 42
Antisense RNAi Oligonucleotide to Inhibit HSP47 for Fibrosis - Drug Profile 43
CAB-101 - Drug Profile 44
CALY-001 - Drug Profile 46
CWHM-12 - Drug Profile 47
Drugs for Fibrosis - Drug Profile 48
elafibranor - Drug Profile 49
G-XXX - Drug Profile 57
IB-DMD - Drug Profile 58
IBIOCFB-03 - Drug Profile 59
ISTH-1106 - Drug Profile 62
KL-01045 - Drug Profile 63
Monoclonal Antibodies for Fibrosis - Drug Profile 64
Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile 65
Monoclonal Antibody 2 for Fibrosis - Drug Profile 66
Monoclonal Antibody for Fibrotic Scar - Drug Profile 67
Monoclonal Antibody to Activate BMP7 for Fibrosis - Drug Profile 68
NCE-401 - Drug Profile 69
Neumomir - Drug Profile 70
NMIL-121 - Drug Profile 71
PAT-048 - Drug Profile 75
phenylbutyrate - Drug Profile 76
PL-5028 - Drug Profile 77
PRI-724 - Drug Profile 78
Proteins for Central Nervous System Disorders and Fibrosis - Drug Profile 80
RBM-003 - Drug Profile 81
RBM-007 - Drug Profile 82
SB-061 - Drug Profile 83
Small Molecule for Fibrosis - Drug Profile 85
Small Molecule for Fibrosis - Drug Profile 86
Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases - Drug Profile 87
Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile 88
Small Molecule to Inhibit MGAT2 for Metabolic Disorders and Fibrotic Diseases - Drug Profile 89
Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile 90
Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile 91
Small Molecules for Fibrosis - Drug Profile 92
Small Molecules for Fibrosis - Drug Profile 93
Small Molecules for Fibrosis - Drug Profile 94
Small Molecules for Fibrosis - Drug Profile 95
Small Molecules for Fibrosis - Drug Profile 96
Small Molecules for Fibrosis and Inflammatory Diseases - Drug Profile 97
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 98
Small Molecules to Agonize GPCR for Fibrosis - Drug Profile 99
Small Molecules to Agonize RARG for Fibrosis - Drug Profile 100
Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile 101
Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile 102
Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology - Drug Profile 103
SRI-31277 - Drug Profile 104
ST-2001 - Drug Profile 105
ST-2022 - Drug Profile 106
Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology - Drug Profile 107
TTX-330 - Drug Profile 108
X-165 - Drug Profile 109
XOMA-089 - Drug Profile 110
Fibrosis - Dormant Projects 111
Fibrosis - Product Development Milestones 114
Featured News & Press Releases 114
Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 117
Disclaimer 118

List of Tables

Number of Products under Development for Fibrosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Fibrosis - Pipeline by Acceleron Pharma Inc, H2 2017
Fibrosis - Pipeline by Aelis Farma SAS, H2 2017
Fibrosis - Pipeline by Anima Biotech Ltd, H2 2017
Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2017
Fibrosis - Pipeline by Cellmid Ltd, H2 2017
Fibrosis - Pipeline by Clementia Pharmaceuticals Inc, H2 2017
Fibrosis - Pipeline by Complexa Inc, H2 2017
Fibrosis - Pipeline by Confo Therapeutics, H2 2017
Fibrosis - Pipeline by EA Pharma Co Ltd, H2 2017
Fibrosis - Pipeline by Five Prime Therapeutics Inc, H2 2017
Fibrosis - Pipeline by Genfit SA, H2 2017
Fibrosis - Pipeline by GlycoMimetics Inc, H2 2017
Fibrosis - Pipeline by iBio Inc, H2 2017
Fibrosis - Pipeline by Inception Sciences Inc, H2 2017
Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2017
Fibrosis - Pipeline by Kadmon Corp LLC, H2 2017
Fibrosis - Pipeline by Kalyra Pharmaceuticals Inc, H2 2017
Fibrosis - Pipeline by Morphic Therapeutic Inc, H2 2017
Fibrosis - Pipeline by Neumedicines Inc, H2 2017
Fibrosis - Pipeline by Novartis AG, H2 2017
Fibrosis - Pipeline by Palatin Technologies Inc, H2 2017
Fibrosis - Pipeline by Proximagen Ltd, H2 2017
Fibrosis - Pipeline by Redx Pharma Plc, H2 2017
Fibrosis - Pipeline by Ribomic Inc, H2 2017
Fibrosis - Pipeline by Scholar Rock Inc, H2 2017
Fibrosis - Pipeline by SciFluor Life Sciences LLC, H2 2017
Fibrosis - Pipeline by SK Chemicals Co Ltd, H2 2017
Fibrosis - Pipeline by Symic Biomedical Inc, H2 2017
Fibrosis - Dormant Projects, H2 2017
Fibrosis - Dormant Projects, H2 2017 (Contd..1), H2 2017
Fibrosis - Dormant Projects, H2 2017 (Contd..2), H2 2017